英格兰常规成人COVID-19疫苗接种规划的成本效果
研究利用英格兰2023至2024年COVID-19住院、ICU入住和死亡数据及定制健康经济成本,评估不同年龄和风险组的疫苗支付意愿阈值。阈值从年轻无风险组的不足1英镑到老年合并症组的超过100英镑,呈强烈非线性年龄依赖;2023年秋季65岁及以上和春季75岁及以上接种提议与仅计管理成本的预购疫苗成本效果阈值一致,未来计入疫苗成本后年龄阈值将缓慢上升。
要点
- 支付意愿阈值从年轻无风险组的不足1英镑到老年合并症组的超过100英镑,呈非线性年龄依赖。
- 2023年秋季65岁及以上和春季75岁及以上接种提议与仅计管理成本的预购疫苗成本效果阈值一致。
- 未来计入疫苗成本后年龄阈值将缓慢上升,凸显保护最年长和最脆弱人群的持续重要性。
核心结论
- 支付意愿阈值呈强烈非线性年龄依赖,从年轻无风险组的不足1英镑到老年合并症组的超过100英镑。
- 尽管疫苗效果估计方法不同,支付意愿阈值及成本效果接种年龄存在相当定性一致。
- 2023年秋季65岁及以上和春季75岁及以上接种提议与仅计管理成本的预购疫苗成本效果阈值一致;未来计入疫苗成本后年龄阈值将缓慢上升,凸显保护最年长和最脆弱人群的持续重要性。
研究设计与样本
- 研究使用英格兰2023年和2024年COVID-19住院、ICU入住和死亡数据,结合定制健康经济成本,评估不同年龄和风险组的疫苗支付意愿阈值。
主要发现
- 支付意愿阈值从年轻无风险组的不足1英镑到老年合并症组的超过100英镑。
- 阈值对年龄呈极端非线性依赖。
- 尽管疫苗效果估计方法不同,支付意愿阈值及成本效果接种年龄存在相当定性一致。
- 2023年秋季65岁及以上和春季75岁及以上接种提议与仅计管理成本的预购疫苗成本效果阈值一致。
- 未来计入疫苗成本后年龄阈值将缓慢上升。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In England, and many other countries, immunity to SARS-CoV-2 infection and COVID-19 disease is highly heterogeneous. Immunity has been acquired through natural infection, primary and booster vaccination, while protection has been lost through waning immunity and viral mutation. During the height of the pandemic in England, the main aim was to rapidly protect the population and large supplies of vaccine were pre-purchased, eliminating the need for cost-effective calculations. As we move to an era where for the majority of the population SARS-CoV-2 infections cause relatively mild disease, and vaccine stocks need to be re-purchased, it is important we consider the cost-effectiveness and economic value of COVID-19 vaccination programmes. Here using data from 2023 and 2024 in England on COVID-19 hospital admissions, ICU admissions and deaths, coupled with bespoke health economic costs, we consider the willingness to pay threshold for COVID-19 vaccines in different age and risk groups. Willingness to pay thresholds vary from less than £1 for younger age-groups without any risk factors, to over £100 for older age-groups with comorbidities that place them at risk. This extreme non-linear dependence on age, means that despite the different method of estimating vaccine effectiveness, there is considerable qualitative agreement on the willingness to pay threshold, and therefore which ages it is cost-effective to vaccinate. The historic offer of COVID-19 vaccination to those 65 and over for the autumn 2023 programme and those over 75 for the spring 2023 programme, aligns with our cost- effective threshold for pre-purchased vaccine when the only cost was administration. However, for future programmes, when vaccine costs are included, the age-thresholds slowly increase thereby demonstrating the continued importance of protecting the eldest and most vulnerable in the population.
引用
- Keeling MJ, Hill EM, Petrou S, et al. Cost-effectiveness of routine COVID-19 adult vaccination programmes in England. Vaccine. 2025. PMID: 40023905. doi:10.1016/j.vaccine.2025.126948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。